High levels of C-reactive protein (CRP), a protein that is produced in response to inflammation, contribute to heart tissue damage that accompanies heart attack and stroke.
Recent research: A new drug called bis-(phosphocholine)-hexane has been shown in laboratory studies to block CRP's tissue-damaging effects. The drug is the first to selectively inhibit CRP.
Next: Clinical trials on bis(phosphocholine)-hexane are expected to begin within the next two years.
Want to Keep Reading?
Continue reading with a Health Confidential membership.
Sign up now
Already have an account? Sign in
You’ve successfully subscribed to Health Confidential
Welcome back! You’ve successfully signed in.
Great! You’ve successfully signed up.
Your link has expired
Success! Check your email for magic link to sign-in.